<DOC>
	<DOCNO>NCT00953225</DOCNO>
	<brief_summary>Vitamin D promote differentiation prostate cancer cell , maintains differentiate phenotype prostate epithelial cell , induce prostate cancer cell death , raise possibility vitamin D deficiency time promote progression subclinical prostate cancer clinical disease . The investigator propose conduct clinical study aim measure efficacy vitamin D3 ( 4000IU/day ) supplementation Veterans diagnose low-risk , early-stage prostate cancer , elect disease monitor active surveillance . The successful completion propose clinical study allow u determine whether correct vitamin D deficiency Veterans diagnose early-stage prostate cancer prevent progression disease improve prognosis .</brief_summary>
	<brief_title>Vitamin D Supplementation Veterans With Early-Stage Prostate Cancer</brief_title>
	<detailed_description>Vitamin D promote differentiation prostate cancer ( PCa ) cell , maintains differentiate phenotype prostate epithelial cell , induce prostate cancer cell death , raise possibility vitamin D deficiency time promote progression subclinical PCa clinical disease . These consideration support use vitamin D3 chemopreventive agent . We hypothesize daily dose vitamin D3 ( 4,000 IU ) take one year Veterans diagnose low-risk , early-stage PCa , eligible active surveillance : ) result measurable decrease serum PSA level significant number enrol subject , b ) associate stabilization improvement PCa pathology , assess histological examination prostate tissue biopsy specimen ( Gleason score percent positive biopsy ) obtain end study , part standard medical care active surveillance . This VA Merit application propose conduct randomize , placebo-controlled clinical study aim measure efficacy vitamin D3 ( 4000IU/day ) supplementation Veterans diagnose early-stage prostate cancer , elect disease monitor active surveillance ( consider definitive therapy ) . The main objective propose clinical study follow : 1 . To determine whether daily supplement 4,000 IU vitamin D3 take twelve month result measurable significant decrease serum PSA level Veterans diagnose low-risk , early stage PCa ( Gleason score 6 , PSA 10 , clinical stage T1C T2a ) , elect disease monitor active surveillance least one year . 2 . To determine enrolled Veterans pathology status PCa analyze prostate tissue biopsy specimens end study ( Gleason score percentage positive biopsy ) , compare obtain enrollment study , part standard medical care . The implementation propose study allow u ass whether vitamin D3 supplementation utilize chemopreventive regimen Veterans diagnose low-risk , early stage PCa , provide useful addition active surveillance .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Male Veterans ( &gt; 18 year age ) recently diagnose lowrisk PCa ( histologically document adenocarcinoma prostate ) A serum PSA value 10.0 ng/ml , Gleason score six less ( three less either architectural pattern ) For purpose eligibility , additional criterion verify : *serum creatinine 2.0 mg/dL serum phosphate ( measure phosphorus ) &gt; 2.3 &lt; 4.8 mg/dL serum calcium &gt; 8.5 &lt; 10.5 mg/dL Subjects concurrent malignancy , except nonmelanoma skin cancer Subjects history sarcoidosis Subjects history highdose ( 1,000 IU per day ) vitamin D supplementation Subjects history hypercalcemia Subjects use lithium medication</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>vitamin D</keyword>
</DOC>